Fatal attraction? The rise of disease management programmes in Europe by Goodwin, Dr. Nick
1
International Journal of Integrated Care – Vol. 7, 24 September 2007 – ISSN 1568-4156 – http://www.ijic.org/
Editorial
Fatal attraction? The rise of disease management
programmes in Europe
On my travels to conferences around Europe, but par-
ticularly in the UK, it is clear that disease management
commands wide support as the ‘optimal’ approach to
planning and delivering health care. It has been wel-
comed as a ‘system response’ to problems evident in
all health services including: the growing burden of
long-term chronic diseases; the lack of integrated
care; the bias towards acute treatment; and the rela-
tive neglect of primary and community alternatives.
The rise of disease management in Europe has also
been rapid. In Germany, for example, disease man-
agement programmes (DMPs) were introduced by law
in 2002 for diabetes, breast cancer, coronary heart dis-
ease, and COPD w1x. Parts of the Netherlands, Spain
and Sweden have similarly begun DMP experimenta-
tions w2, 3x. In England, policy has focused on adopt-
ing US managed care models of the type implemented
by Kaiser Permanente and United HealthCare’s Ever-
care model of case management w4x.
For policy-makers, the theory behind disease manage-
ment is immediately attractive as a basis for system
reform since it makes the dual claim that health care
resources can be used more cost-effectively (through
vertical integration) whilst simultaneously improving
andyor maintaining good health for the individual
patient. However, engaging with the debate in Europe
reveals that the foundations for the ‘movement’ appear
to be based on exaggerated and unrealistic claims. At
least three fundamental problems exist: the lack of a
common understanding to the concept of disease
management; lack of evidence on its long-term
cost-effectiveness; and, significantly, little evidence to
support its claims for better health outcomes.
The first problem is immediately apparent at interna-
tional conferences where the concept of disease man-
agement is perceived in very different ways. The term,
for example, is used synonymously with a range of
related but different concepts including: case manage-
ment, care management, managed care, shared care,
transmural care, integrated care, care pathways,
chains of care, self-care and so on. This is perhaps
not surprising given that disease management is a
very broad concept and is multi-component in nature.
Differences in our understanding, therefore, are born
from the heterogeneity of components unique to every
DMP that—as one systematic review of the evidence
points out—largely precludes any general conclusions
to be made about their collective effectiveness w5x.
Clearly, there is a need for a more rigorous interpre-
tation of the concept of disease management to enable
more reliable syntheses and conclusions.
The second problem concerns the weakness of
the evidence on the cost-effectiveness of DMPs. In
England, for example, much of the empirical justifica-
tion for current system reform cites a few (well publi-
cized) studies from the USA that have reported how
DMPs can have a significant impact on reducing
unplanned admissions and length of hospitalisation
whilst reducing rates of complications from chronic dis-
eases and retaining patient satisfaction levels w6–8x.
The argument is persuasive and compelling to the
converted, but it is also very clear from the wider data
available from DMP studies that the case for disease
management in general is inconclusive. We just don’t
know whether disease management in Europe is a
more cost-effective solution than standard care in the
long term.
This is a problematic realisation. The ‘tipping point’ for
the growing disease management movement in
Europe was primarily based on the premise that it
would help alleviate the foreseen long-term economic
time-bomb of aging populations and the growing bur-
den of chronic diseases. Aspects of disease manage-
ment have since been aggressively implemented as a
lever to break the traditional authority of physicians as
health systems seek multi-professional, multi-discipli-
nary solutions with a focus on ‘upstream’ prevention
and the promotion of well-being. Should the approach
prove unfounded—that long-term cost-effectiveness
and improved health outcomes remain elusive—then
clinicians and patients are likely to reject disease man-
agement policies in much the same manner that has
led to the current demise of the HMO movement in
the USA.
The third problematic observation is that the debate
progresses with relatively little evidence (even con-
cern) for improved patient outcomes. It is true that
most DMPs that have been evaluated in appropriately
designed studies have been shown to be effective
compared to ‘standard’ or ‘usual’ care in improving the
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least measured by proxies such as providers’ compli-
ance to set standards of care and the ability of
patients’ to monitor their disease w5x. The less good
news is that the evidence appears limited to diabetes,
depression and coronary heart disease with benefits
being inconclusive in other cases. Moreover, there is
little long-term knowledge on benefits to mortality or
morbidity and what evidence does exist suggests no
statistically significant differences. Most important,
perhaps, is that every DMP trial appears different in
design and so complex that we cannot be certain
about what combination of components are responsible
for any particular result.
So what can we conclude from these observations? It
is clear that there is never going to be a single model
of disease management in Europe that can be univer-
sally applied, but it is essential that evaluations and
lessons from experience—using a common concep-
tual framework—are collated to show the long-term
cost-effectiveness of DMPs and whether longer-term
health outcomes can be improved. Furthermore, coun-
tries need to examine critically whether introducing
DMPs—particularly in the form of new organisations—
is necessary when other solutions are available.
For example, in countries like the Netherlands and
England, primary care-based networks that provide
multi-component, integrated and co-ordinated support
over time may be better than DMPs that potentially
preclude more holistic care.
There is certainly a compelling logic to disease man-
agement—and that is often all that is needed to justify
policy reforms—but one gets a sense in which a fatal
attraction has been established in which policy-makers
are being seduced into the latest fashion in healthcare
reform without fully understanding its consequences.
Dr. NickGoodwin
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